Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

07 May 2021: Clinical Research

Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis

Anthony Matta 123ABCDEF , Vanina Bongard 12ABCDEF , Frédéric Bouisset 12ABCDEF , Dorota Taraszkiewicz 12ABCDEF , Jean-Pierre Rabès 4BDEF , Jean Ferrières 12ABCDEFG*

DOI: 10.12659/MSM.928784

Med Sci Monit 2021; 27:e928784

Table 3 A comparison of the responder rate between the 3 groups.

Whole population (n=123)PCSK9i (n=83)PCSK9i+ezetimibe (n=12)PCSK9i+statin and ezetimibe (n=28)
Responders, n (%)61 (49.6%)32 (38.6%)7 (58.3%)22 (78.6%)
Odds ratio2.206
95% Confidence interval(0.6–8.1)(2–17.6)
P value0.240.001
PCSK9i – proprotein convertase subtilisin/kexin type 9 inhibitors.

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750